

Outline of Initial Listing Issue

Company Name	Cuorips Inc.
Scheduled Listing Date	Jun. 27, 2023
Market Section	Growth Market
Current Listed Market	N/A
Name and Title of Representative	KUSANAGI Takayuki, President and CEO
Address of Main Office	Nihonbashi Life Science Building2.507, 3-11-5 Nihonbashi-Honcho, Chuo-ku Tokyo, 103-0023 Tel. +81-3-6231-0043
(Closest Point of Contact)	(Same as above)
Home Page	https://cuorips.co.jp/en/
Date of Incorporation	Mar. 21, 2017
Description of Business	Research, development, manufacturing and sales of Cellular and Tissue-based Products and Cell processing products Contract development and manufacturing services and consulting services of Cellular and Tissue-based Products and Cell processing products
Category of Industry / Code	Pharmaceutical / 4894(ISIN JP3266030000)
Authorized Total No. of Shares to be Issued	22,000,000 shares
No. of Issued Shares	5,857,916 shares (As of May 23, 2023)
No. of Issued Shares (incl. treasury shares) at the Time of Listing	7,557,916 shares (Note 1) The number includes newly issued shares issued through the public offering. (Note 2) The number could increase as a result of the exercise of share options, etc.
Capital	JPY 104,150 thousand (As of May 23, 2023)
No. of Shares per Share Unit	100 shares
Business Year	From Apr. 1 to Mar. 31 of the following year
General Shareholders Meeting	Within 3 months after the end of the business year
Record Date	Mar. 31
Record Date of Surplus Dividend	Sep. 30 and Mar. 31
Transfer Agent	Mitsubishi UFJ Trust and Banking Corporation
Auditor	KPMG AZSA LLC
Managing Trading Participant	Nomura Securities Co.,Ltd.

(Reference Translation)

<Overview of Public Offering / Secondary Offering >

Public Offering / Secondary Offering	Public Offering (Newly Issued Shares) Secondary Offering (Placement Underwritten and Purchased by Principal Underwriting Participants)	1,700,000shares 500,000shares
	Secondary Offering (Placement by over-allotment scheme)	330,000shares
Original Share Offerers	Taiko Pharmaceutical Co., Ltd. Mitsubishi Corporation CellSource Co., Ltd. Others	200,000shares 106,000shares 80,000shares 114,000shares
Offering Price Determination Method	Book-building method	
Provisional Conditions Determination Date	Jun. 8, 2023	
Book-building Period	Jun. 9, 2023 to Jun. 15, 2023	
Offering Price Determination Date	Jun. 16, 2023	
Subscription Period	Jun. 19, 2023 to Jun. 22, 2023	
Payment Date	Jun. 26, 2023	
Settlement Date	Jun. 27, 2023	
Principal Underwriting Participants	Nomura Securities Co.,Ltd. SBI SECURITIES Co.,Ltd. MATSUI SECURITIES CO.,LTD.	

- (Note 1) Tokyo Stock Exchange, Inc. approves new listings based on the results of the examination by Japan Exchange Regulation.
- (Note 2) The “Initial Listing Application Securities Report (Part I)” (only in Japanese) of the company is available on the JPX official website. Please refer to such release for details.
- (Note 3) Buy and sell market orders for this issue are prohibited in transactions carried out up to and including the initial price determination date.